M Simon1, J Boström, P Koch, J Schramm. 1. Neurochirurgische Universitätsklinik, Sigmund-Freud-Str 25, 53105 Bonn. Matthias.Simon@ukb.uni-bonn.de
Abstract
OBJECTIVE: To document and critically analyse the impact of the revised WHO 2000 histological classification for meningiomas on postoperative radiotherapy/radiosurgery indications and MRI follow up protocols. METHODS: The current (2000) WHO classification was used to grade 57 meningiomas treated surgically at one institution. These had been reviewed previously in 1999. All German neurosurgical departments carrying out intracranial microsurgery were asked to detail their guidelines for radiation therapy and follow up for meningiomas of different WHO grades. RESULTS: Use of the current criteria downgraded seven of 15 atypical meningiomas (WHO grade II, MII) to grade I (MI), and four of six anaplastic tumours (WHO grade III, MIII) to grade II. Indications for radiotherapy/radiosurgery and MRI follow up protocols varied substantially with the histological grade and between institutions--for example, after an incomplete resection, radiotherapy/radiosurgery recommendations differed between MI and MII in 30 of 58 units (52%), and between MII and MIII in 34 of 56 units (61%). CONCLUSIONS: Correlative studies combining treatment and outcome data with a standardised histopathological analysis are warranted to define properly the indications for radiotherapy/radiosurgery and follow up protocols after surgery for meningiomas of different histological grades. The use of changing grading paradigms during recent years renders decision making based on local and published experience difficult. The relatively large number of meningiomas classified as atypical/WHO grade II in current practice would argue against an uncritically aggressive approach to these tumours.
OBJECTIVE: To document and critically analyse the impact of the revised WHO 2000 histological classification for meningiomas on postoperative radiotherapy/radiosurgery indications and MRI follow up protocols. METHODS: The current (2000) WHO classification was used to grade 57 meningiomas treated surgically at one institution. These had been reviewed previously in 1999. All German neurosurgical departments carrying out intracranial microsurgery were asked to detail their guidelines for radiation therapy and follow up for meningiomas of different WHO grades. RESULTS: Use of the current criteria downgraded seven of 15 atypical meningiomas (WHO grade II, MII) to grade I (MI), and four of six anaplastic tumours (WHO grade III, MIII) to grade II. Indications for radiotherapy/radiosurgery and MRI follow up protocols varied substantially with the histological grade and between institutions--for example, after an incomplete resection, radiotherapy/radiosurgery recommendations differed between MI and MII in 30 of 58 units (52%), and between MII and MIII in 34 of 56 units (61%). CONCLUSIONS: Correlative studies combining treatment and outcome data with a standardised histopathological analysis are warranted to define properly the indications for radiotherapy/radiosurgery and follow up protocols after surgery for meningiomas of different histological grades. The use of changing grading paradigms during recent years renders decision making based on local and published experience difficult. The relatively large number of meningiomas classified as atypical/WHO grade II in current practice would argue against an uncritically aggressive approach to these tumours.
Authors: S L Stafford; B E Pollock; R L Foote; M J Link; D A Gorman; P J Schomberg; J A Leavitt Journal: Neurosurgery Date: 2001-11 Impact factor: 4.654
Authors: J Debus; M Wuendrich; A Pirzkall; A Hoess; W Schlegel; I Zuna; R Engenhart-Cabillic; M Wannenmacher Journal: J Clin Oncol Date: 2001-08-01 Impact factor: 44.544
Authors: J P Maire; M Caudry; J Guérin; D Célérier; F San Galli; N Causse; R Trouette; M Dautheribes Journal: Int J Radiat Oncol Biol Phys Date: 1995-09-30 Impact factor: 7.038
Authors: John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes Journal: Cancer Immunol Immunother Date: 2020-07-13 Impact factor: 6.968
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: Ryan L Lym; Quinn T Ostrom; Carol Kruchko; Marta Couce; Daniel J Brat; David N Louis; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2015-04-12 Impact factor: 4.130
Authors: Stephanie E Combs; Lutz Edler; Iris Burkholder; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Andreas Unterberg; Wolfgang Wick; Jürgen Debus; Renate Haselmann Journal: BMC Cancer Date: 2010-11-09 Impact factor: 4.430
Authors: C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-29 Impact factor: 7.038
Authors: Gurvinder Kaur; Eli T Sayegh; Andrew Larson; Orin Bloch; Michelle Madden; Matthew Z Sun; Igor J Barani; C David James; Andrew T Parsa Journal: Neuro Oncol Date: 2014-04-02 Impact factor: 12.300
Authors: Naureen Keric; Darius Kalasauskas; Christian F Freyschlag; Jens Gempt; Martin Misch; Alicia Poplawski; Nicole Lange; Ali Ayyad; Claudius Thomé; Peter Vajkoczy; Bernhard Meyer; Florian Ringel Journal: J Neurooncol Date: 2020-01-03 Impact factor: 4.130
Authors: Liangjuan Fang; Daniel E Lowther; Matthew L Meizlish; Richard C E Anderson; Jeffrey N Bruce; Lesley Devine; Anita J Huttner; Steven H Kleinstein; Jae-Yun Lee; Joel N H Stern; Gur Yaari; Laura Lovato; Katharine M Cronk; Kevin C O'Connor Journal: Neuro Oncol Date: 2013-08-26 Impact factor: 12.300
Authors: Chenyang Wang; Tania B Kaprealian; John H Suh; Charlotte D Kubicky; Jeremy N Ciporen; Yiyi Chen; Jerry J Jaboin Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300